Antimicrobial resistance is a growing threat, with treatment options urgently needed for patients at risk of MDR Gram-negative infections1,2cUTI pasient
Identifying patients at risk of MDR Gram-negative infections is vital for appropriate selection of adequate, early antimicrobial therapy to reduce the risk of fatal outcomes.2cUTI patient profile*
Identifying patients with cUTI at high-risk of MDR Gram-negative infections.
- Undergoing chemotherapy following mastectomy for node-positive, left-sided breast cancer
- Neutropenic (chemotherapy related)
- Recent carbapenem treatment
- Presented with frequent urination and flank pain
- Infection symptoms include:
- Symptoms ongoing for >36 hours
Patient risk factors for a MDR
cUTI with sepsis
K. pneumoniae, including those resistant to carbapenems (KPC)
Listen to Gian Maria Rossolini
Why ZAVICEFTA is an appropriate choice for your cUTI patients
ZAVICEFTA: As effective as best available therapy with Gram-negative cUTI.12Explore moreInfectious Thinking
From the Department of Experimental and Clinical Medicine, University of Florence, Italy as he provides an in-depth introduction to diagnostics and susceptibility testing.
Listen to episode 6 of our ‘Infectious Thinking’ podcast on critically ill CRE cUTI patients.
Learn more about our cUTI clinical trial efficacy.
View ZAVICEFTA prescribing information.
Footnotes:*The example described here is not an actual patient, but rather a fictitious representation of a scenario for which ZAVICEFTA (ceftazidime–avibactam) could be considered.
†Avibactam does not inhibit class B enzymes (metallo-β-lactamases) and does not inhibit many class D enzymes.8
§To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.8
¶The total duration shown may include intravenous Zavicefta followed by appropriate oral therapy.8Abbreviations:COPD, chronic obstructive pulmonary disease; CRE, carbapenem-resistant Enterobacterales; cUTI, complicated urinary tract infection; ESBL, extended spectrum beta-lactamase; HAP, hospital-acquired pneumonia; ICU, intensive care unit; KPC, Klebsiella pneumoniae carbapenemase; MDR, multidrug-resistant; OXA, oxacillinase; VAP, ventilator-associated pneumonia.References:Timsit J-F, et al. Intensive Care Med 2019; 45:573–91.Bonine NG, et al. Am J Med Sci 2019;357:102–10.Bassetti M, et al. Exp Rev Anti Infect Ther 2017;15:55–65.Miller BM, et al. Am J Infect Control 2016;44:134–7.De Waele J, et al. Intensive Care Med 2018;44:189–96.Albur M, et al. Ann Clin Microbiol Antimicrob 2016;15:23.Harris AD, et al. Emerg Infect Dis 2007;13:1144–9.ZAVICEFTA. Summary of Product Characteristics, 2022.Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–71.Zhanel GG, et al. Drugs 2013;73:159–77.Mazuski JE, et al. Surg Infect 2017;18:1–76.Carmeli Y, et al. Lancet Infect Dis 2016;16:661–73.Torres A, et al. Lancet Infect Dis 2018;18:285–95.Mazuski JE, et al. Clin Infect Dis 2016;62:1380–9.Wagenlehner FM, et al. Clin Infect Dis 2016;63:754–62.
PP-ZVA-NOR-0141 Mai 2023